BALTIMORE PEDIATRIC AIDS CLINICAL TRIALS GROUP

该巴尔的摩儿科ACTG，约翰之间的合作努力 霍普金斯大学和马里兰州大学于1988年获得了 为感染艾滋病毒的儿童提供临床试验机会的意图 整个巴尔的摩市和马里兰州。 以来 PBACTG在25个方案中招募了244名儿童， 最小的后续损失，并大大有助于 ACTG议程，为主要科学委员会提供主席， 礼宾主席和礼宾团队成员。 这两个机构仍然高度致力于继续和扩大 这些合作努力。 我们建议继续这些活动 重点是四个科学领域中的每一个， PACTG CORC：围产期传播，主要治疗， 机会性感染和免疫学，因此，BPACTG将 继续参与围产期试验、I期、II期和III期试验， 以及评估免疫疗法的试验。 鉴于我们 机构资源，我们相信这些领域代表优势 在BPACTG中，我们将在以下领域做出贡献 在很大程度上，ACTG的科学领导地位。 最近的问题， 登记和数据管理已经确定， 由BACTG领导层处理。 因此，我们预计 入组人数远远超过方案规定的最低初治艾滋病毒感染者人数， 儿童和艾滋病毒感染的孕妇需要RFA。 我们 我希望继续我们的高入学率和保留少数民族 反映了该区域艾滋病毒感染的人口统计数据， 并通过加强外联工作和与JHU的合作， 和UMAB青少年诊所，我们希望增加我们的招生人数， 感染艾滋病毒的青少年。 在过去的8年里，我们 建立了有效的研究人员和提供者网络 BPACTG为艾滋病毒感染青年和孕妇提供服务， 地区BPACTG增加了新的调查人员， 加强每个或我们的个别单位，并通过我们的 我们目前拥有的能力，组织， 与社区建立联系，成功地为艾滋病毒感染者提供 婴儿、儿童、青少年和孕妇， 获得ACTG临床试验。

The Baltimore Pediatric ACTG, a collaborative effort between Johns Hopkins and the University of Maryland, was funded in 1988 with the intent of providing access to clinical trials for HIV-infected children throughout the city of Baltimore and the state of Maryland. Since its inception, the PBACTG has enrolled 244 children in 25 protocols with minimal loss to follow-up and has contributed substantially to the ACTG agenda, providing the chairs for major scientific committees, protocol chairs, and protocol team members. Both institutions remain highly committed to continuing and expanding these collaborative efforts. We propose to continue these activities with an emphasis on each of the four scientific areas prioritized by the PACTG CORC: perinatal transmission, primary therapy, opportunistic infections and immunology, Thus, the BPACTG will continue to participate in perinatal trials, phase I, II and III trials, and in trials evaluating immune-based therapy. Given our institutional resources, we believe these areas represent strengths within the BPACTG and are areas in which we will contribute substantially to the ACTG scientific leadership. Recent problems with enrollment and data management have been identified and are being addressed by the BPACTG leadership. We therefore anticipate enrolling well over the minimum number of protocol naive HIV-infected children and HIV-infected pregnant women required by the RFA. We expect to continue our high enrollment ang retention of minority groups, reflecting the demographics of HIV infection in the region, and through increased outreach efforts and collaboration with the JHU and UMAB Adolescent Clinics we expect to increase our enrollment of HIV-infected adolescents. During the past 8 years we have established an effective network of researchers and providers in the BPACTG who serve the HIV-infected youth and expectant women of the region. The addition of new investigators to the BPACTG has further strengthened each or our individual units and through our collaborative efforts we currently have the capability, organization, and linkages with the community to successfully provide HIV-infected infants, children, adolescents and pregnant women of the region with access to ACTG clinical trials.